NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. Last updated 18-Jun-19 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as indicated by (TA) Release NICE Adherence of local formulary to NICE Titles are hyperlinks to Yes N/A Date of local Date of local Time to full guidance (mark 'x' if (mark 'x' if decision decision implement applicable) applicable) Due (90 days) Made (days) 2018-19 TA517 Avelumab for Avelumab for treating metastatic Merkel cell carcinoma. 1 treating metastatic 11/04/2018 Evidence-based recommendations on avelumab (Bavencio) for treating metastatic X 10/07/2018 17/12/2018 250 Merkel cell carcinoma (secondary) Merkel cell carcinoma in adults. TA518 Tocilizumab for Tocilizumab for treating giant cell arteritis. 1 treating giant cell 18/04/2018 Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell X 17/07/2018 16/07/2018 89 arteritis arteritis in adults. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after TA519 Pembrolizumab platinum-containing chemotherapy. for treating locally Evidence-based recommendations on pembrolizumab (Keytruda) for previously advanced or metastatic treated locally advanced or metastatic urothelial carcinoma in adults. 1 urothelial carcinoma 25/04/2018 X 24/07/2018 04/05/2018 9 after platinum- containing chemotherapy TA520 - Atezolizumab Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced for treating locally or metastatic non-small-cell lung cancer after chemotherapy in adults. advanced or metastatic 1 16/05/2018 X 14/08/2018 18/06/2018 33 non-small-cell lung cancer after chemotherapy TA521 - Guselkumab Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to for treating moderate to severe plaque psoriasis in adults. 1 13/06/2018 X 11/09/2018 16/07/2018 33 severe plaque psoriasis TA522 - Evidence-based recommendations on pembrolizumab (Keytruda) for untreated Pembrolizumab for locally advanced or metastatic urothelial carcinoma in adults. untreated locally advanced or metastatic NICE is aware that European Medicines Agency’s Committee for Medicinal Products urothelial cancer when for Human Use (CHMP) has recommended restricting the use of pembrolizumab as a cisplatin is unsuitable first line-treatment for patients with urothelial cancer ineligible for cisplatin-based 1 13/06/2018 X 11/09/2018 18/06/2018 5 chemotherapy. It has said that pembrolizumab should now only be used for first-line treatment of urothelial cancer in adults ineligible for cisplatin-based chemotherapy with high levels of PD-L1. The CHMP opinion will be forwarded to the European Commission, which will issue a final legally binding licensing decision applicable in all EU Member States. TA523 - Midostaurin for Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3- 1 untreated acute myeloid 13/06/2018 mutation-positive acute myeloid leukaemia in adults. x 11/09/2018 22/08/2018 70 leukaemia TA524 - Brentuximab Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating vedotin for treating CD30-positive Hodgkin lymphoma in adults. CD30-positive Hodgkin 1 lymphoma 13/06/2018 This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for x 11/09/2018 22/08/2018 70 treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446. TA525 - Atezolizumab Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated for treating locally locally advanced or metastatic urothelial carcinoma in adults. advanced or metastatic 1 urothelial carcinoma 13/06/2018 There is separate guidance on atezolizumab for people with untreated disease who X 11/09/2018 18/06/2018 5 after platinum- cannot have cisplatin-based chemotherapy. containing chemotherapy TA526 - Arsenic trioxide Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute for treating acute promyelocytic leukaemia in adults. 1 13/06/2018 x 11/09/2018 22/08/2018 70 promyelocytic leukaemia TA527 - Beta Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, interferons and Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults. glatiramer acetate for 1 treating multiple 27/06/2018 This guidance replaces NICE technology appraisal guidance 32 on beta interferon X 25/09/2018 19/10/2018 114 sclerosis and glatiramer acetate for the treatment of multiple sclerosis. TA528 - Niraparib for Evidence-based recommendations on niraparib (Zejula) for treating relapsed, maintenance treatment platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary of relapsed, platinum- peritoneal cancer that has responded to the most recent course of platinum-based 1 04/07/2018 x 02/10/2018 16/07/2018 12 sensitive ovarian, chemotherapy in adults. fallopian tube and peritoneal cancer TA529 - Crizotinib for Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive treating ROS1-positive advanced non-small-cell lung cancer in adults. 1 04/07/2018 x 02/10/2018 16/07/2018 12 advanced non-small- cell lung cancer TA530 - Nivolumab for Evidence-based recommendations on nivolumab (Opdivo) for treating locally treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had advanced unresectable platinum-containing chemotherapy. or metastatic urothelial . 1.1 Nivolumab is not cancer after platinum- recommended, within its marketing authorisation, for treating locally advanced containing unresectable or metastatic urothelial carcinoma in adults who have had platinum- 1 chemotherapy 04/07/2018 containing therapy. x 02/10/2018 16/07/2018 12 1.2 This recommendation is not intended to affect treatment with nivolumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as indicated by (TA) Release NICE Adherence of local formulary to NICE Titles are hyperlinks to Yes N/A Date of local Date of local Time to full guidance (mark 'x' if (mark 'x' if decision decision implement applicable) applicable) Due (90 days) Made (days) 2018-19 TA531 - 18/07/2018 Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD- Pembrolizumab for L1-positive metastatic non-small-cell lung cancer in adults. untreated PD-L1- 1 X 16/10/2018 09/08/2018 22 positive metastatic This guidance replaces NICE technology appraisal guidance 447. non-small-cell lung cancer TA532 - Cenegermin 18/07/2018 Evidence-based recommendations on cenegermin (Oxervate) for treating for treating neurotrophic keratitis in adults. 1 X 16/10/2018 10/08/2018 23 neurotrophic keratitis Cenegermin is not recommended, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults. TA533 - Ocrelizumab 25/07/2018 Evidence-based recommendations on ocrelizumab (Ocrevus) for treating for treating relapsing–remitting multiple sclerosis in adults. 1 relapsing–remitting X 23/10/2018 16/07/2018 0 multiple sclerosis TA534 - Dupilumab 01/08/2018 Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to for treating moderate severe atopic dermatitis in adults. 1 X 30/10/2018 22/08/2018 21 to severe atopic dermatitis TA492 - Atezolizumab 02/07/2018 Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1- for untreated PD-L1- positive locally advanced or metastatic urothelial carcinoma in adults. positive locally advanced or ! July 2018: The European Medicines Agency restricted the use of atezolizumab for metastatic urothelial untreated urothelial carcinoma. It should now only be used in adults with high levels 1 cancer when cisplatin of PD-L1. For more information, see the summary of product characteristics for X 10/10/2018 09/08/2018 38 atezolizumab. is unsuitable There is separate guidance on atezolizumab for people who have had cisplatin- based chemotherapy. TA522 - 24/07/2018 Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD- Pembrolizumab for L1-positive locally advanced or metastatic urothelial carcinoma in adults. untreated PD-L1- positive locally ! July 2018: The European Medicines Agency restricted the use of pembrolizumab 1 advanced or metastatic for untreated urothelial carcinoma. It should now only be used in adults with high X 22/10/2018 09/08/2018 16 urothelial cancer when levels of PD-L1. For more information, see the summary of product characteristics for cisplatin is unsuitable pembrolizumab. TA535 - Lenvatinib and 08/08/2018 Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) sorafenib for treating for progressive, locally advanced or metastatic differentiated thyroid cancer in adults 1 differentiated thyroid who have had radioactive iodine. X 06/11/2018 09/08/2018 1 cancer after radioactive iodine TA536 - Alectinib for 08/08/2018 Evidence-based recommendations on alectinib (Alecensa)